Anavex Life Sciences Corp.AVXLNASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank73
3Y CAGR-7.2%
5Y CAGR+1.2%
Studio
Year-over-Year Change

Expenses from normal business operations (SG&A, R&D, etc.)

3Y CAGR
-7.2%/yr
vs +18.0%/yr prior
5Y CAGR
+1.2%/yr
Recent deceleration
Acceleration
-25.1pp
Decelerating
Percentile
P73
Within normal range
vs 5Y Ago
1.1x
Modest growth
Streak
3 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$44.60M-13.2%
2025$51.41M-2.8%
2024$52.88M-5.2%
2023$55.76M+9.4%
2022$50.99M+21.4%
2021$42.00M+35.8%
2020$30.94M+7.4%
2019$28.81M+50.2%
2018$19.18M+23.5%
2017$15.54M-